在患有非便秘性易怒肠综合征的患者中,基因素1受体对抗剂埃巴斯的剂量依赖作用
Fedrica Pia1, Lisse Decraecker1, Danny De Looze2
1Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.
高剂量的埃巴斯显著改善了易怒肠综合征 (IBS) 的症状,特别是腹痛. 这项研究表明,ebastine 40mg与20mg相比,在没有便秘的IBS患者中提供了更好的症状控制.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 刺激性肠综合征 (IBS) 治疗往往无法缓解腹痛,这是一个关键症状.
- 巨细胞和基因素受体1 (H1R) 激活与内脏过敏症 (VHS) 和IBS疼痛有关.
- 以前的试验表明,ebastine是一种H1R抗剂,对非便秘性IBS有希望.
研究的目的:
- 为了比较ebastine 40mg与20mg在治疗非便秘IBS患者中的疗效.
- 为了评估增加埃巴斯剂量对腹痛和其他胃肠道症状的影响.
主要方法:
- 一项开放性研究比较了12周内在非便秘IBS患者中服用20mg (n=92) 和40mg (n=73) 的ebastine.
- 在基线和12周使用视觉模拟量表 (VAS) 评估的腹痛.
- 使用GSRS问卷进行评估的胃肠道症状.
主要成果:
- 与20mg相比,Ebastine 40mg显著增加了腹痛反应者 (62%对32%) 和实质性反应者 (40%对12%) 的百分比.
- 随着40mg的eBastine (-1.0与0.4) 的使用,观察到腹严重性的显著减少.
结论:
- 埃巴斯丁40毫克在管理非便秘性IBS症状,特别是腹痛方面表现出比20毫克更高的疗效.
- 这些发现支持进一步研究用于IBS治疗的高剂量埃巴斯.
更多相关视频
03:50Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
05:26Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
Published on: March 1, 2024
相关概念视频
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome III: Medical and Nursing Management
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
